Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4749090 | 0.91 | CNR1 (0.49) | CNR1 | |
| SCHEMBL972697 | 0.81 | PDE4B (0.49) | CNR1CNR2LPAR5PDE4BALDH1A1 | |
| SCHEMBL4694446 | 0.81 | PDE4B (0.47) | CNR1CNR2LPAR5PDE4BALDH1A1 | |
| SCHEMBL4694434 | 0.81 | CNR1 (0.41) | CNR1CNR2LPAR5PDE4BALDH1A1 | |
| SCHEMBL4822288 | 0.81 | PDE4B (0.48) | CNR1CNR2LPAR5PDE4BALDH1A1 | |
| SCHEMBL973098 | 0.78 | CNR1 (0.48) | CNR1CNR2LPAR5PDE4BALDH1A1 | |
| SCHEMBL5346005 | 0.77 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL4184217 | 0.75 | CNR1 (0.53) | CNR1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5339252 | 0.74 | CNR1 (0.51) | CNR1CNR2PDE4B | |
| SCHEMBL6123512 | 0.74 | CNR1 (0.69) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874779-A1 | ACYLAMINOBICYCLIC HETEROMATIC COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
| WO-2006111849-A1 | ACYLAMINOBICYCLIC HETEROMATIC COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241100-A1 | Acylaminobicyclic heteroaromatic compounds and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885LPAR5 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.